Etanercept
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00005 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 21 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | rheumatoid vasculitis | KG + DL |
| 2 | hypermobility of coccyx | KG + DL |
| 3 | inflammatory spondylopathy | KG + DL |
| 4 | Kummell disease | KG + DL |
| 5 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 6 | vertebral disease | KG + DL |
| 7 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | KG + DL |
| 8 | rheumatoid nodulosis | KG + DL |
| 9 | juvenile chronic polyarthritis | KG + DL |
| 10 | WHIM syndrome | KG + DL |
| 11 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | KG + DL |
| 12 | brachydactyly-syndactyly syndrome | KG + DL |
| 13 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 14 | leukoplakia | KG + DL |
| 15 | psoriasis-related juvenile idiopathic arthritis | KG + DL |
| 16 | Richter syndrome | KG + DL |
| 17 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 18 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 19 | acute lymphoblastic/lymphocytic leukemia | KG + DL |
| 20 | metastatic neoplasm | KG + DL |
| 21 | malignant spiradenoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.